Sam Brusco12.19.22
Abbott Labs has gained U.S. Food and Drug Administration (FDA) approval for its new Eterna spinal cord stimulation system (SCS). The company claims Eterna is the smallest implantable, rechargeable SCS currently available on the market to treat chronic pain.
Eterna SCS uses Abbott’s low-dose BurstDR stimulation, an SCS waveform technology that has clinical 1A evidence proven to reduce pain 23% more than traditional waveform tech. BurstDR mimics natural firing patterns found in the brain for pain relief.
New Xtend energy technology requires Eterna to be recharged as few as five times per year under standard use from a wireless charger. TotalScan MRI tech allows for full-body MRI scans with the SCS implant.
Eterna SCS can adapt to future innovations without replacing the implant. A patient-focused mobile app facilitates real-time battery life and charging status updates for Eterna on a personal or Abbott-provided Apple device.
"Abbott's low-dose BurstDR stimulation is clinically proven to reduce pain, improve people's ability to perform everyday activities, and reduce emotional suffering associated with pain," Timothy Deer, M.D., DABPM, president and CEO of the Spine and Nerve Centers of the Virginias told the press. "Until now, it wasn't available on a rechargeable device that was this small, and that only needs to be charged a few times a year. This makes a big difference in comfort for many patients who now can have access to the best of both worlds—a small, best-in-class rechargeable device with superior stimulation therapy."
"At Abbott, we deliver products and solutions with the goal of simplifying healthcare, improving clinical outcomes and providing people suffering from chronic pain with the best experience possible. As we progress on this commitment, Eterna is the next major leap forward," added Pedro Malha, VP, neuromodulation, Abbott. "Eterna is the smallest rechargeable spinal cord stimulator on the market, provides the longest therapy between charges and offers an optimized recharging experience—all key features when selecting the best overall system."
Eterna SCS uses Abbott’s low-dose BurstDR stimulation, an SCS waveform technology that has clinical 1A evidence proven to reduce pain 23% more than traditional waveform tech. BurstDR mimics natural firing patterns found in the brain for pain relief.
New Xtend energy technology requires Eterna to be recharged as few as five times per year under standard use from a wireless charger. TotalScan MRI tech allows for full-body MRI scans with the SCS implant.
Eterna SCS can adapt to future innovations without replacing the implant. A patient-focused mobile app facilitates real-time battery life and charging status updates for Eterna on a personal or Abbott-provided Apple device.
"Abbott's low-dose BurstDR stimulation is clinically proven to reduce pain, improve people's ability to perform everyday activities, and reduce emotional suffering associated with pain," Timothy Deer, M.D., DABPM, president and CEO of the Spine and Nerve Centers of the Virginias told the press. "Until now, it wasn't available on a rechargeable device that was this small, and that only needs to be charged a few times a year. This makes a big difference in comfort for many patients who now can have access to the best of both worlds—a small, best-in-class rechargeable device with superior stimulation therapy."
"At Abbott, we deliver products and solutions with the goal of simplifying healthcare, improving clinical outcomes and providing people suffering from chronic pain with the best experience possible. As we progress on this commitment, Eterna is the next major leap forward," added Pedro Malha, VP, neuromodulation, Abbott. "Eterna is the smallest rechargeable spinal cord stimulator on the market, provides the longest therapy between charges and offers an optimized recharging experience—all key features when selecting the best overall system."